Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
18 studies found for:    Tesamorelin OR Egrifta[TREATMENT] AND HIV [CONDITION]
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Tesamorelin Effects on Liver Fat and Histology in HIV
Conditions: Human Immunodeficiency Virus (HIV);   Nonalcoholic Fatty Liver Disease (NAFLD);   Nonalcoholic Steatohepatitis (NASH)
Interventions: Drug: tesamorelin;   Drug: Placebo
2 Completed Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients
Condition: HIV
Intervention: Drug: Tesamorelin
3 Completed
Has Results
TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy
Conditions: Lipodystrophy;   HIV Infections
Interventions: Drug: Tesamorelin;   Drug: Placebo for Tesamorelin
4 Recruiting Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
Condition: HIV
Intervention: Drug: Tesamorelin for injection
5 Not yet recruiting Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
Condition: Mild Cognitive Impairment
Interventions: Drug: Tesamorelin;   Drug: Placebo
6 Suspended Egrifta Replacement and Sleep Disordered Breathing
Condition: Lipodystrophy
Intervention: Drug: Tesamorelin (Egrifta)
7 Terminated
Has Results
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Drug: Tesamorelin
8 Completed
Has Results
Effects of Growth Hormone Releasing Hormone in HIV
Conditions: HIV;   HIV Lipodystrophy
Interventions: Drug: tesamorelin;   Drug: placebo
9 Recruiting Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
Conditions: Diabetic Retinopathy;   HIV
Interventions: Drug: Tesamorelin;   Drug: Placebo-Control
10 Completed TH9507 in Patients With HIV-Associated Lipodystrophy
Conditions: HIV Infections;   Lipodystrophy
Intervention: Drug: TH9507
11 Completed
Has Results
Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men
Condition: Healthy Volunteers
Intervention: Drug: Growth Hormone Releasing Hormone (Tesamorelin)
12 Completed Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes
Condition: Type 2 Diabetes
Intervention: Drug: TH9507
13 Not yet recruiting Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia
Conditions: Sleep Disorder;   Traumatic Brain Injury
Interventions: Drug: Tesamorelin;   Other: Placebo
14 Recruiting The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment
Condition: Mild Cognitive Impairment
Intervention: Drug: Growth Hormone Releasing Hormone (GHRH)
15 Withdrawn Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue
Condition: Abdominal Obesity
Interventions: Drug: Tesamorelin;   Drug: Placebo
16 Completed
Has Results
Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese
Conditions: Abdominal Obesity;   Growth Hormone Deficiency
Interventions: Drug: Growth hormone releasing hormone (GHRH) 1-44;   Drug: Placebo
17 Completed
Has Results
Effects of Short-term Growth Hormone in HIV-infected Patients
Condition: HIV Lipodystrophy
Interventions: Drug: Growth hormone;   Drug: Growth Hormone Releasing Hormone
18 Completed SMART: Somatotrophics, Memory, and Aging Research Trial
Conditions: Aging;   Mild Cognitive Impairment
Intervention: Drug: TH9507 human growth hormone releasing hormone (GHRH)

Study has passed its completion date and status has not been verified in more than two years.